| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2702161 | Optometry - Journal of the American Optometric Association | 2011 | 6 Pages |
Abstract
Intravitreal bevacizumab has proven to be an effective treatment for choroidal neovascularization and shows a significant improvement of vision for wet AMD patients. However, there are risks associated with the procedure. One of the most visually significant is an RPE tear, which can occur at an incidence rate as high as 17%. Optometrists should be aware of this rare, but serious, complication associated with anti-VEGF treatment for wet AMD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Brenda O.D., Steven O.D.,